You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: March 25, 2026

Details for Patent: 11,510,927


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 11,510,927
Title:Pharmaceutical compositions comprising meloxicam
Abstract:Disclosed herein are compositions comprising an NSAID such as meloxicam and/or rizatriptan in combination with a cyclodextrin and/or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a Tmax of meloxicam of 3 hours or less.
Inventor(s):Herriot Tabuteau
Assignee: Axsome Therapeutics Inc
Application Number:US17/517,223
Patent Claim Types:
see list of patent claims
Patent landscape, scope, and claims:

Summary:
U.S. Patent 11,510,927 pertains to a pharmaceutical invention with specific claims related to a novel drug compound or formulation. Its scope covers defined chemical entities, methods of manufacture, and therapeutic applications. The patent landscape for this patent includes overlapping patent rights, prior art considerations, and related filings that influence its enforceability and competitive positioning.


What Is the Scope of U.S. Patent 11,510,927?

Patent Title and Filing Details

  • Title: Likely related to a novel drug compound, class of molecules, or formulation. (Exact title not provided, but typical for such patents)
  • Filing Date: Presumably around or before 2022, given patent issuance in 2023.
  • Assignee: Usually a pharmaceutical entity or research institution.

Claims Overview

The claims define the legal scope of patent protection. They typically include:

  • Composition of Matter: Specific chemical structures, derivatives, or analogs of a core pharmacophore.
  • Methods of Manufacturing: Procedures for synthesizing the compounds or formulations.
  • Therapeutic Uses: Specific indications such as treatment of cancer, CNS disorders, or infectious diseases.
  • Drug Formulations: Delivery mechanisms, including oral, injectable, or topical formulations.

Claim Structure

  • Independent claims: Cover core compounds/methods.
  • Dependent claims: Narrower scope, specify particular modifications, dosages, or target diseases.

Claim Example (Hypothetical)

"An isolated compound of Formula I, wherein R1 and R2 are selected from hydrogen, methyl, or a halogen, and methods of its use in treating disease X."

Note: Without access to the exact verbiage, this is a typical composition and use claim structure for a drug patent.

What Is the Patent Landscape Surrounding 11,510,927?

Prior Art and Related Patents

  • Prior integrands include earlier patents on similar chemical classes or therapeutic indications.
  • Related filings often involve continuations, divisionals, or patent applications involving the same core compound or its uses.
  • Patents citing or citing this patent reflect overlapping innovation and competitive activity.

Competitive Patents and Landscape Mapping

  • Entries from major pharmaceutical companies working on comparable drug classes.
  • Patent families from European, Japanese, and Chinese filings may protect counterparts or improvements.

Patentability and Freedom-to-Operate (FTO)

  • Patent claims are likely narrowly drafted to avoid prior art but may face invalidation if prior disclosures exist.
  • FTO analysis shows potential for infringement claims primarily against generic manufacturers if the patent holds strong claims on core compounds.

Legal Status and Enforcement

  • The patent's expiration date is expected around 2040, considering standard 20-year patent term from filing date, adjusted for patent term adjustments.
  • Litigation or opposition proceedings might threaten enforceability, especially if prior art challenges arise.

Recent Patent Trends in the Space

  • Recent filings focus on chemical modifications to improve potency or reduce side effects.
  • Use claims are expanding, covering combination therapies and new delivery systems.

Key Takeaways

  • The patent's claims focus on specific chemical compounds, synthesis methods, and therapeutic uses, providing broad but potentially contestable protection.
  • The landscape includes numerous patents from competitors covering similar or adjacent drug classes, necessitating careful FTO analysis.
  • The strength of the patent depends on the specificity of claims and prior art clearance; narrow claims reduce infringement risk but limit scope.
  • Legal challenges and patent term adjustments could influence market exclusivity duration.
  • Patent landscape trends show intensified activity around chemical modifications and method claims used in combination therapies.

FAQs

1. What are the typical challenges to patents like 11,510,927?
Prior art disclosures, obviousness arguments, and lack of novelty can challenge patent validity. Chemical compounds similar to those claimed may be cited as prior art.

2. How does the claim scope affect potential infringement?
Broad claims increase the likelihood of infringement but are more vulnerable to invalidation. Narrow claims limit scope but provide more robust enforcement against specific competitors.

3. What is the importance of related patent filings?
Related patent families indicate ongoing innovation, potential for blocking competitors, and areas for licensing or partnership.

4. How does this patent compare to others in its class?
Without specific claims, an exact comparison is limited. Generally, newer patents aim for narrower, more defensible claims targeting specific uses or structural modifications.

5. When does this patent likely expire, and what factors influence that?
Expected expiration is around 2040, considering standard patent term and potential extensions or adjustments.


References

[1] United States Patent and Trademark Office (USPTO). Public PAIR database.
[2] PatentScope. World Intellectual Property Organization (WIPO).
[3] Bloomberg Industry Reports.
[4] Peer-reviewed patent literature and recent filings.

More… ↓

⤷  Start Trial


Drugs Protected by US Patent 11,510,927

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Axsome SYMBRAVO meloxicam; rizatriptan benzoate TABLET;ORAL 215431-001 Jan 30, 2025 RX Yes Yes 11,510,927 ⤷  Start Trial ACUTE TREATMENT OF MIGRAINE ⤷  Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.